RNS Number : 5052U
Centrica PLC
29 March 2019
 

Centrica plc (the 'Company')

29 March 2019

Notification of Transactions of Directors

On 29 March 2019 the Company granted options to employees under the Centrica Sharesave Scheme (the "Scheme"). This grant of options over Centrica plc ordinary shares of 614/81 pence ("Shares") under the Scheme included certain Persons Discharging Managerial Responsibility.

The following notifications, made pursuant to Article 19 of the Market Abuse Regulation, provide further details.   

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1.    Richard Hookway

2.    Chris O'Shea

2

Reason for the notification

a)

Position/status

1.    Executive Director

2.    Executive Director

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Centrica plc

b)

LEI

E26EDV109X6EEPBKVH76

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial

instrument, type of instrument

 

Identification code

Ordinary shares of 614/81 pence

 

 

GB00B033F229

b)

Nature of the transaction

1.    Grant of three year options over Shares under the Company's Sharesave Scheme

2.    Grant of five year options over Shares under the Company's Sharesave Scheme

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1.    £0.987

2.    £0.987

1.    18,237

2.    30,395

d)

Aggregated information

 

Aggregated volume

 

-      Price

 

-      Total

 

 

N/A

 

 

e)

Date of the transaction

29 March 2019

f)

Place of the transaction

Off market

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHPGUCPWUPBGGB